ASCENDO BIOTECHNOLOGY, INC. TAIWAN BRANCH (CAYMAN ISLANDS)
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Their lead asset, ASD141, is a first‑in‑class monoclonal antibody that blocks the innate immune checkpoint TLT‑1 to reshape the tumor microenvironment and enhance anti‑tumor immunity.
They are also developing ASD001, an antibody aimed at rebalancing over
They are also developing ASD001, an antibody aimed at rebalancing over
The content above was translated by Ai
Founded Year
2019
Unified Business No.
85070076
Status
Active
Number of Employees
12
Total Paid-in
Capital
- (NT$)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ascendo Biotechnology, founded in 2019, is a clinical‑stage biotech company developing novel immunotherapies by targeting innate immune pathways to treat cancer and autoimmune diseases.
The content above was translated by Ai
